Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Lung cancer is the leading cause of death worldwide for both men and women. Surgery can
be offered as a radical treatment at stages I and II and selected cases of stage III (III A) …

Introduction This study evaluated the addition of gefitinib to sequential or concurrent
chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer. Methods …

Purpose This study aimed to compare erlotinib (E) and etoposide/cisplatin (EP) with
concurrent radiation therapy (RT) for patients with stage IIIA/B unresectable advanced non …

Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with
technologic strides in radiotherapy have the potential to improve outcomes for patients with …

Over the past decade, a multitude of targeted agents have been explored in the treatment of
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …

In recent years there has been undoubted progress in the evaluation and development of
targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the …

PURPOSE: To establish the safety profile and efficacy of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) concurrent with individualized radiotherapy (RT) in …

The combination of radiotherapy (RT) with targeted agents in non-small cell lung cancer
(NSCLC) has been expected to improve the therapeutic ratio and tumor control. The EGFR …

INTRODUCTION: A feasibility study was performed to examine the safety and toxicity profile
of daily gefitinib (250mg) administration with concurrent definitive thoracic radiation therapy …